The mean age was 66.3 and 66.5 years in the fondaparinux group and nadroparin
calcium group, respectively (Student's t-test, p=0.749).
All of the trials reported a lower incidence of colorectal adenomas in the
calcium group. The meta-analysis determined that subjects who received calcium experienced a 10% to 15% lower risk of adenoma recurrence compared with those who received the placebo.
However, by 1-month postpartum, those in the
calcium group had significantly lower NTx/BAP ratios than those in the placebo group (p = 0.04) indicating a net reduction in bone loss in the supplement group by the end of follow-up.
In the present study between the
Calcium Group (1500 mg CaCO3 + 400IU Vit.D/kg) and Ca/Vit.D Group (1500 mg CaCO3 + 400IU Vit.D/kg and 500 IU Vit.D/kg) no significant differences were seen in bone healing.
The
calcium group developed hypertension 8 weeks later than control group and the 3 weeks duration was statistically a significant difference (p < 0.049).
In the pooled analysis, the incidence of gastrointestinal adverse events was 43% higher in the
calcium group than in the placebo group (p < 0.001).
The cheese and yogurt groups showed a statistically significant correlation with the
calcium group. Only the cheese group showed a statistically significant correlation with the phosphorus group.
Since the women didn't know if they were in the
calcium group or the placebo group, the researchers allowed those who were taking calcium when they entered the study to continue it on their own.
By 5 years of follow-up, there were a total of 101 myocardial infarctions, strokes, and sudden deaths in 69 women in the supplemental
calcium group, and 54 such events in 42 controls (BMJ 2008;336:262-6).
By 5 years of follow up, there were a total of 101 myocardial infarctions, strokes, and sudden deaths in 69 women in the supplemental
calcium group compared with 54 such events in 42 control subjects (BMJ 2008;336:262-6).
A total of 21 of the 732 women in the
calcium group experienced 24 myocardial infarctions, a statistically significant difference vs.